Welcome to our dedicated page for PEAR news (Ticker: PEAR), a resource for investors and traders seeking the latest updates and insights on PEAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PEAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PEAR's position in the market.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced a new study highlighting the real-world effectiveness of its FDA-authorized digital therapeutic, reSET-O. This 12-month analysis revealed a significant $3,832 average reduction in healthcare costs per Medicaid patient and a 28% decrease in inpatient stays, along with improved adherence to buprenorphine therapy. These findings underscore reSET-O's potential in managing opioid use disorder and reducing overall healthcare resource utilization, reinforcing its role in addressing the opioid crisis.
Pear Therapeutics (NASDAQ: PEAR) has announced interim results from the DREAM trial, demonstrating significant reductions in insomnia, anxiety, and depression symptoms in adults using Somryst, its FDA-authorized prescription digital therapeutic. Data showed that patients treated with Somryst over nine weeks exhibited notable improvements in Insomnia Severity Index, PHQ-8, and GAD-7 scores, with lasting effects observed up to six months post-treatment. This highlights the efficacy of Somryst as a leading digital therapy for chronic insomnia.
Pear Therapeutics (NASDAQ: PEAR) announced a study revealing that reSET®, the first FDA-authorized prescription digital therapeutic for substance use disorder, significantly reduced hospital encounters and healthcare costs. Over six months post-treatment, hospital visits dropped by 50%, leading to a cost saving of approximately $3,591 per patient. This analysis of 101 patients substantiates the economic value and effectiveness of reSET in improving treatment outcomes for various substance use disorders, reinforcing Pear's commitment to innovative digital health solutions.
Pear Therapeutics, Inc. (Nasdaq: PEAR) announced its participation in the Jefferies Healthcare Conference scheduled for June 8-10, 2022, in New York City. The CFO and COO, Chris Guiffre, will present on June 10, at 9:30 AM EDT. Investors can arrange one-on-one meetings through Jefferies. A live audio webcast of the presentation will be available here and can be accessed later for 30 days on Pear’s website. Pear specializes in prescription digital therapeutics (PDTs) for various conditions.
Pear Therapeutics has released data showing that its digital therapeutic, reSET-O®, for opioid use disorder (OUD) is effective across diverse U.S. regions, including urban and rural areas. Presented at the APA Annual Meeting, the study evaluated 5,263 patients and found similar engagement levels with reSET-O, highlighting its potential to improve access to behavioral treatments. Median engagement metrics included 21-23 days active in the app, 25-28 lessons completed, and 76-80% retention during weeks 9-12. The findings emphasize the importance of health equity in treatment access.
Pear Therapeutics, trading as PEAR on Nasdaq, announced its inaugural virtual Investor Day on June 6, 2022, from 10:00 a.m. to 12:30 p.m. ET. The event will showcase updates on their three prescription digital therapeutics (PDTs) focused on substance use disorder, opioid use disorder, and chronic insomnia. Management will discuss commercial progress and expansion of access to PDTs. A live webcast will be available on their website, with a replay accessible for 30 days following the event.
Pear Therapeutics reported a strong first quarter for 2022, achieving revenue of $2.7 million, up 108% from Q4 2021 and significantly higher than $376,000 in Q1 2021. Over 9,200 prescriptions were filled for its three FDA-authorized products. Key operational highlights include expanded access through agreements with Michigan and Oklahoma Medicaid, and a new HCPCS code from CMS for reimbursement of digital therapeutics. The company aims to reach $22 million in revenue for 2022, with a forecast of 50,000 to 60,000 prescriptions.
Pear Therapeutics expands its telehealth services for opioid use disorder with QuickMD, enabling eligible patients access to reSET-O. This program aligns with data showing a rise in overdose deaths, highlighting the significance of telemedicine during the pandemic. reSET-O offers cognitive behavioral therapy and clinical dashboards for clinicians. Executives emphasized the importance of accessible care amidst the ongoing addiction crisis, aiming to reduce stigma and provide support from the comfort of patients’ homes.
Pear Therapeutics, Inc. (Nasdaq: PEAR) will present at the 17th Annual Needham Technology & Media Conference on May 18, 2022, at 8:00 a.m. ET. Chris Guiffre, CFO and COO, will deliver the virtual presentation. Opportunities for one-on-one meetings will also be available through Needham & Company. A live audio webcast can be accessed here and will be available on Pear's website for 30 days post-event. Pear is a leader in prescription digital therapeutics, with products for substance use disorder, opioid use disorder, and chronic insomnia.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced its participation in the Bank of America 2022 Healthcare Conference in Las Vegas on May 10. The company's President and CEO, Corey McCann, will engage in an analyst-led fireside chat at 10:40 a.m. Pacific Time. Interested parties can access the live audio webcast here or via Pear's website, where a replay will be available for 30 days post-event. Pear is known for its prescription digital therapeutics aimed at improving patient outcomes.
